Tonix Pharmaceuticals (TNXP) Competitors $28.37 +0.66 (+2.38%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$28.42 +0.05 (+0.19%) As of 09/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. MAZE, PHAR, SPRY, ATAI, CRON, UPB, CRMD, SYRE, QURE, and ABUSShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Maze Therapeutics (MAZE), Pharming Group (PHAR), ARS Pharmaceuticals (SPRY), atai Life Sciences (ATAI), Cronos Group (CRON), Upstream Bio (UPB), CorMedix (CRMD), Spyre Therapeutics (SYRE), uniQure (QURE), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Maze Therapeutics Pharming Group ARS Pharmaceuticals atai Life Sciences Cronos Group Upstream Bio CorMedix Spyre Therapeutics uniQure Arbutus Biopharma Tonix Pharmaceuticals (NASDAQ:TNXP) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations. Do analysts recommend TNXP or MAZE? Tonix Pharmaceuticals presently has a consensus price target of $70.00, indicating a potential upside of 146.74%. Maze Therapeutics has a consensus price target of $32.67, indicating a potential upside of 39.13%. Given Tonix Pharmaceuticals' higher possible upside, research analysts clearly believe Tonix Pharmaceuticals is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has stronger earnings & valuation, TNXP or MAZE? Maze Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M24.66-$130.04M-$39.47-0.72Maze Therapeutics$167.50M6.15$52.23MN/AN/A Does the media prefer TNXP or MAZE? In the previous week, Maze Therapeutics had 18 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 24 mentions for Maze Therapeutics and 6 mentions for Tonix Pharmaceuticals. Maze Therapeutics' average media sentiment score of 0.62 beat Tonix Pharmaceuticals' score of -0.50 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Maze Therapeutics 9 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TNXP or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -828.22%. Maze Therapeutics' return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-828.22% -57.93% -51.04% Maze Therapeutics N/A N/A N/A Do insiders and institutionals believe in TNXP or MAZE? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryMaze Therapeutics beats Tonix Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.90M$2.55B$5.78B$10.28BDividend YieldN/A57.29%5.74%4.64%P/E Ratio-0.7223.4276.9426.98Price / Sales24.66721.40543.88128.54Price / CashN/A169.7137.1760.63Price / Book0.895.4313.836.37Net Income-$130.04M$32.95M$3.29B$271.46M7 Day Performance-0.84%2.04%1.57%2.53%1 Month Performance-22.34%8.20%6.87%9.42%1 Year Performance89.26%-2.34%81.59%30.16% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.1711 of 5 stars$28.37+2.4%$70.00+146.7%+95.5%$242.90M$10.09M-0.7250News CoverageMAZEMaze Therapeutics3.5561 of 5 stars$23.79-4.1%$30.17+26.8%N/A$1.04B$167.50M0.00121Analyst ForecastInsider TradePHARPharming Group2.2506 of 5 stars$14.95+1.0%$30.00+100.7%+77.2%$1.02B$297.20M-115.00280SPRYARS Pharmaceuticals2.5389 of 5 stars$10.11-0.4%$32.50+221.4%-29.3%$996.90M$89.15M-20.5990ATAIatai Life Sciences3.2629 of 5 stars$4.66+1.2%$11.25+141.7%+280.6%$991.31M$2.31M-6.7080News CoverageCRONCronos Group1.7385 of 5 stars$2.57-0.6%N/A+17.6%$982.11M$117.61M51.30450UPBUpstream Bio1.6075 of 5 stars$18.09+0.9%$56.50+212.4%N/A$974.96M$2.37M0.0038CRMDCorMedix3.9472 of 5 stars$13.04-0.4%$18.00+38.0%+61.4%$973.44M$43.47M17.3930Insider TradeSYRESpyre Therapeutics2.6167 of 5 stars$15.88-2.0%$53.40+236.3%-47.1%$959.45M$890K-4.6773Analyst ForecastQUREuniQure2.7599 of 5 stars$17.04+0.6%$37.45+119.8%+155.9%$934.93M$14.34M-4.35500ABUSArbutus Biopharma2.0333 of 5 stars$4.68-4.6%$5.00+7.0%+7.0%$901.95M$6.17M-16.2290 Related Companies and Tools Related Companies Maze Therapeutics Alternatives Pharming Group Alternatives ARS Pharmaceuticals Alternatives atai Life Sciences Alternatives Cronos Group Alternatives Upstream Bio Alternatives CorMedix Alternatives Spyre Therapeutics Alternatives uniQure Alternatives Arbutus Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
